Chimerix (NASDAQ:CMRX) Shares Pass Below 200-Day Moving Average of $1.00

Chimerix, Inc. (NASDAQ:CMRX)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.00 and traded as low as $0.90. Chimerix shares last traded at $0.91, with a volume of 506,516 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on CMRX shares. Wedbush reaffirmed an “outperform” rating and set a $6.00 target price on shares of Chimerix in a research note on Monday, February 12th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research note on Friday, March 1st. Finally, StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research report on Monday, March 4th.

Chimerix Trading Down 1.7 %

The company’s 50 day moving average price is $1.08 and its two-hundred day moving average price is $1.00. The stock has a market cap of $80.65 million, a P/E ratio of -0.98 and a beta of 1.15.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Chimerix had a negative return on equity of 37.93% and a negative net margin of 25,337.96%. On average, sell-side analysts anticipate that Chimerix, Inc. will post -0.77 earnings per share for the current year.

Institutional Trading of Chimerix

Institutional investors and hedge funds have recently made changes to their positions in the business. Engineers Gate Manager LP bought a new position in shares of Chimerix during the 1st quarter worth $54,000. Ergoteles LLC purchased a new stake in Chimerix in the first quarter worth about $65,000. Price T Rowe Associates Inc. MD bought a new position in Chimerix during the 3rd quarter worth about $28,000. Dynamic Technology Lab Private Ltd purchased a new position in Chimerix during the 1st quarter valued at about $66,000. Finally, Cetera Investment Advisers bought a new stake in shares of Chimerix in the 1st quarter valued at about $77,000. 45.42% of the stock is currently owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.